Physician profile
Deepali Sharma
NPI 1306058581
$3,715.48
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.79 · 2020: $2,066 · 2021: $1,095 · 2022: $536.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,531.92 | 2021-2022 | |
| Puma Biotechnology, INC. | $1,000.00 | 2020 | |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Kite Pharma, INC. | $114.83 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $19.79 | 2019 | |
| Eisai INC. | $19.22 | 2020 | |
| Sirtex Medical INC | $15.58 | 2022 | |
| Innate Pharma, INC | $14.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.